Smithkline Beecham Corporation

Smith Kline & French Laboratories Limited

John Kitteringham

Gary Thomas Borrett

Rodney C Young

Roderick Alan Porter

Mythily Vimal

Mark R Shipton

Mark Jason Hughes

Steven Mark Bromidge

Erol A Faruk

Joseph Marian Fortunak

Jeffery L Wood

Nicholas Sisti

Martyn Voyle

John Keogh

Brian P Slingsby

Nitrosation process

A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate, or hydtrate thereof, processes for preparing said compounds and pharmaceutical compostions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Enantiomer of carbazole derivative as 5-HT1-like agonists

A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists. ##STR1##

Process for preparing enantiomers of carbazole derivatives as 5-HT.sub.1

A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1 represents ##STR2## in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;

Process for the preparation of azabicycloc derivatives

Derivatives of quinuclidine n-oxide as muscarinic receptor ligands

##STR1## A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Enantiomers of carbazole derivatives as 5-HT.sub. 1-like agonists

Process for preparing an enantiomer of a carbazole derivative

Process of preparing enantiomers of carbazole derivatives

A (+)or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

Enantiomers of carbazole derivatives as 5-HT.sub.1 -like agonists

##STR1## A process for preparing compounds of formula (I), by nitrosating compounds of formula (II), compounds of formula (I) having pharmaceutical activity.

The present invention provides a process for the asymmetric synthesis of camptothecin analogs as well as novel chemical intermediates of Formula I, II, and III. In general, the present process comprises conversion of a cis dioxolanone, having the same desired absolute configuration as the desired camptothecin analog, to a compound of Formula I, II, or III, which compound is then converted to the desired camptothecin analog. ##STR1##

Process for asymmetric total synthesis of camptothecin analogues

The present invention provides a process for the asymmetric synthesis of camptothecin analogues as well as novel chemical intermediates of Formula I, II, and III. In general, the present process comprises conversion of a cis dioxolanone, having the same desired absolute configuration as the desired camptothecin analogue, to a compound of Formula I, II, or III, which compound is then converted to the desired camptothecin analogue. ##STR1##

This invention provides a process for the preparation of pyrimidinone compounds with a group R.sup.2 CH(OH)-- at the 5-position thereof, wherein R.sup.2 is an optionally substituted acid-stable 5- or 6-membered nitrogen-containing heteroaryl group. The pyrimidinone ring is further substituted by a side-chain of a H.sub.1 -antagonist or H.sub.2 -antagonist or a precursor thereof. The compounds are convertible to 5-heteroaryl methyl compounds which are either useful H.sub.1 - or H.sub.2 -antagonists or precursors thereof.

Growing community of inventors

Hertford, United Kingdom

John Kitteringham